Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities

Surabhi M Talele; Afroz Shareef Mohammad; Julia A. Schulz; Bjoern Bauer; Anika M.S. Hartz; Jann N Sarkaria; William F. Elmquist

doi:10.1007/978-3-030-88773-5_24

Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities

Surabhi M Talele, Afroz Shareef Mohammad, Julia A. Schulz, Bjoern Bauer, Anika M.S. Hartz, Jann N Sarkaria, William F. Elmquist

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Multiple hurdles pose challenges in identifying drugs that may be effective in treating brain tumors, including limited central nervous system (CNS) distribution of therapeutics, heterogeneous disruption of the blood-brain barrier in the regions of the tumor that lead to heterogenous drug distribution within the tumor, and genetic heterogeneity of tumor drivers. This chapter discusses the current standard of care and its limitations, as well as complex challenges in the treatment of primary and metastatic brain tumors. We review a variety of prospective delivery solutions of therapeutics to the brain and CNS for the treatment of brain tumors that will in the future lead to opening new doors for more effective treatments.

Original language	English (US)
Title of host publication	AAPS Advances in the Pharmaceutical Sciences Series
Publisher	Springer
Pages	723-762
Number of pages	40
DOIs	https://doi.org/10.1007/978-3-030-88773-5_24
State	Published - 2022

Publication series

Name	AAPS Advances in the Pharmaceutical Sciences Series
Volume	33
ISSN (Print)	2210-7371
ISSN (Electronic)	2210-738X

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the National Institutes of Health [Grants RO1 NS107548, U54 CA210180, U01 CA227954]. The authors would also like to thank the editors of the book for their comments and valuable inputs.

Publisher Copyright:
© 2022, American Association of Pharmaceutical Scientists.

Keywords

Active transporters
Antibody drug conjugates
Blood-tumor barrier
Glioblastoma
Immunotherapy
Receptor mediated transport

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/978-3-030-88773-5_24

Find It

Find It at U of M Libraries

Cite this

Talele, S. M., Mohammad, A. S., Schulz, J. A., Bauer, B., Hartz, A. M. S., Sarkaria, J. N., & Elmquist, W. F. (2022). Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities. In AAPS Advances in the Pharmaceutical Sciences Series (pp. 723-762). (AAPS Advances in the Pharmaceutical Sciences Series; Vol. 33). Springer. https://doi.org/10.1007/978-3-030-88773-5_24

Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities. / Talele, Surabhi M; Mohammad, Afroz Shareef; Schulz, Julia A. et al.
AAPS Advances in the Pharmaceutical Sciences Series. Springer, 2022. p. 723-762 (AAPS Advances in the Pharmaceutical Sciences Series; Vol. 33).

Research output: Chapter in Book/Report/Conference proceeding › Chapter

@inbook{7093275671304054aa12e547fc1bb807,

title = "Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities",

abstract = "The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Multiple hurdles pose challenges in identifying drugs that may be effective in treating brain tumors, including limited central nervous system (CNS) distribution of therapeutics, heterogeneous disruption of the blood-brain barrier in the regions of the tumor that lead to heterogenous drug distribution within the tumor, and genetic heterogeneity of tumor drivers. This chapter discusses the current standard of care and its limitations, as well as complex challenges in the treatment of primary and metastatic brain tumors. We review a variety of prospective delivery solutions of therapeutics to the brain and CNS for the treatment of brain tumors that will in the future lead to opening new doors for more effective treatments.",

keywords = "Active transporters, Antibody drug conjugates, Blood-tumor barrier, Glioblastoma, Immunotherapy, Receptor mediated transport",

author = "Talele, {Surabhi M} and Mohammad, {Afroz Shareef} and Schulz, {Julia A.} and Bjoern Bauer and Hartz, {Anika M.S.} and Sarkaria, {Jann N} and Elmquist, {William F.}",

note = "Funding Information: Acknowledgments This work was supported by the National Institutes of Health [Grants RO1 NS107548, U54 CA210180, U01 CA227954]. The authors would also like to thank the editors of the book for their comments and valuable inputs. Publisher Copyright: {\textcopyright} 2022, American Association of Pharmaceutical Scientists.",

year = "2022",

doi = "10.1007/978-3-030-88773-5_24",

language = "English (US)",

series = "AAPS Advances in the Pharmaceutical Sciences Series",

publisher = "Springer",

pages = "723--762",

booktitle = "AAPS Advances in the Pharmaceutical Sciences Series",

}

TY - CHAP

T1 - Drug Delivery to Primary and Metastatic Brain Tumors

T2 - Challenges and Opportunities

AU - Talele, Surabhi M

AU - Mohammad, Afroz Shareef

AU - Schulz, Julia A.

AU - Bauer, Bjoern

AU - Hartz, Anika M.S.

AU - Sarkaria, Jann N

AU - Elmquist, William F.

N1 - Funding Information: Acknowledgments This work was supported by the National Institutes of Health [Grants RO1 NS107548, U54 CA210180, U01 CA227954]. The authors would also like to thank the editors of the book for their comments and valuable inputs. Publisher Copyright: © 2022, American Association of Pharmaceutical Scientists.

PY - 2022

Y1 - 2022

N2 - The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Multiple hurdles pose challenges in identifying drugs that may be effective in treating brain tumors, including limited central nervous system (CNS) distribution of therapeutics, heterogeneous disruption of the blood-brain barrier in the regions of the tumor that lead to heterogenous drug distribution within the tumor, and genetic heterogeneity of tumor drivers. This chapter discusses the current standard of care and its limitations, as well as complex challenges in the treatment of primary and metastatic brain tumors. We review a variety of prospective delivery solutions of therapeutics to the brain and CNS for the treatment of brain tumors that will in the future lead to opening new doors for more effective treatments.

AB - The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Multiple hurdles pose challenges in identifying drugs that may be effective in treating brain tumors, including limited central nervous system (CNS) distribution of therapeutics, heterogeneous disruption of the blood-brain barrier in the regions of the tumor that lead to heterogenous drug distribution within the tumor, and genetic heterogeneity of tumor drivers. This chapter discusses the current standard of care and its limitations, as well as complex challenges in the treatment of primary and metastatic brain tumors. We review a variety of prospective delivery solutions of therapeutics to the brain and CNS for the treatment of brain tumors that will in the future lead to opening new doors for more effective treatments.

KW - Active transporters

KW - Antibody drug conjugates

KW - Blood-tumor barrier

KW - Glioblastoma

KW - Immunotherapy

KW - Receptor mediated transport

UR - http://www.scopus.com/inward/record.url?scp=85130959139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130959139&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-88773-5_24

DO - 10.1007/978-3-030-88773-5_24

M3 - Chapter

AN - SCOPUS:85130959139

T3 - AAPS Advances in the Pharmaceutical Sciences Series

SP - 723

EP - 762

BT - AAPS Advances in the Pharmaceutical Sciences Series

PB - Springer

ER -

Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities

Abstract

Publication series

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this